Viral infections: New options to fight Ebola

Affiliations

Comment

Cláudio Nunes-Alves. Nat Rev Drug Discov. 2015 Jun.

. 2015 Jun;14(6):385.

doi: 10.1038/nrd4642.

No abstract available

Comment on

Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates.
Marzi A, Halfmann P, Hill-Batorski L, Feldmann F, Shupert WL, Neumann G, Feldmann H, Kawaoka Y. Marzi A, et al. Science. 2015 Apr 24;348(6233):439-42. doi: 10.1126/science.aaa4919. Epub 2015 Mar 26. Science. 2015. PMID: 25814063 Free PMC article.
Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial.
Zhu FC, Hou LH, Li JX, Wu SP, Liu P, Zhang GR, Hu YM, Meng FY, Xu JJ, Tang R, Zhang JL, Wang WJ, Duan L, Chu K, Liang Q, Hu JL, Luo L, Zhu T, Wang JZ, Chen W. Zhu FC, et al. Lancet. 2015 Jun 6;385(9984):2272-9. doi: 10.1016/S0140-6736(15)60553-0. Epub 2015 Mar 25. Lancet. 2015. PMID: 25817373 Clinical Trial.
Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.
Thi EP, Mire CE, Lee AC, Geisbert JB, Zhou JZ, Agans KN, Snead NM, Deer DJ, Barnard TR, Fenton KA, MacLachlan I, Geisbert TW. Thi EP, et al. Nature. 2015 May 21;521(7552):362-5. doi: 10.1038/nature14442. Epub 2015 Apr 22. Nature. 2015. PMID: 25901685 Free PMC article.